Navigation Links
In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
Date:1/12/2009

MARSEILLE, France, January 12 /PRNewswire-FirstCall/ -- IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops and markets molecular diagnostic products for leukemia and breast cancer has launched 3 new products during the fourth quarter of 2008, that expand its leukemia molecular diagnostic portfolio:

    - FusionQuant BCR-ABL IVD kit, used in the the detection and monitoring
      of chronic myeloid leukemias (CML), is a new CE marked expanded
      version of our existing product. The new IVD kit now provides all the
      necessary components in one package adding convenience and efficiency
      in the lab. The improved kit will also support the much needed test
      standardisation required for proper disease monitoring

    - ProfileQuant CLLU1, in chronic lymphocytic leukemia (CLL).
      This research kit provides prognostic information, and has the
      potential to play a significant role in the monitoring of this disease.

    - MutaScreen MPL, a research kit for the detection of MPL mutations in
      JAK2 negative myeloproliferative neoplams (MPN), is a significant
      addition to the MPD family of products that Ipsogen offers.

These 3 new tests exemplify Ipsogen's strategy of (i) introducing technological and scientific innovation to address unmet diagnostic needs, and (ii) rapidly translating scientific discoveries into patient bedside tools, in line with the ultimate objective of enabling better and more personalised disease management.

"In the last quarter of 2008, we launched 3 new products. With 21 kits now in distribution, of which 10 are CE marked, Ipsogen's molecular diagnostic portfolio covers a significant range of the leukemia spectrum. These new products will help hematologists refine and improve treatment strategies" says Stephane Debono, COO and in charge of product planning..

Vincent Fert, CEO, concludes: 'These 3 new product launches are in line with our 2008 plans, and will further equip our sales staff with a comprehensive and market leading range of leukemia products that helps consolidate our leadership position in this growing market'.

Next Press Release announcement - Full-year Sales 2008: 18 February 2009 (after market)

About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 48 people as of December 31, 2008. Its headquarters are located in Marseilles, France. The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: http://www.ipsogen.com


'/>"/>
SOURCE Ipsogen SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
2. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
3. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
4. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
5. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
6. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
7. Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
10. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
11. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
(Date:3/22/2017)... ... 2017 , ... Researchers face a fundamental challenge as they ... tissues, bones, even whole organs to implant in people to treat disease or ... the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t fabricate ...
(Date:3/22/2017)... , March 22, 2017   iSpecimen ®, ... that Doctors Pathology Service (DPS), a full-service ... the United States , has joined ... Health Information Network (DHIN) to make human biospecimens ... The novel program, announced in 2015 as a ...
(Date:3/22/2017)... Pa. , March 22, 2017 /PRNewswire/ ... global independent provider of product and service ... today that it has acquired EPL Archives, ... supports customers across the entire regulated product ... archive sample, document storage and ancillary services. ...
Breaking Biology Technology:
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):